Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Metastasis | Research

Prognosis prediction in esophageal signet-ring-cell carcinoma: a competing risk analysis

Authors: Chen Chen, Zehua Wang, Yanru Qin

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Objective

This study aims to construct and validate a competing risk nomogram model to predict 1-year, 3-year, and 5-year cancer-specific survival (CSS) for patients with esophageal signet-ring-cell carcinoma.

Methods

Patients diagnosed with esophageal signet-ring-cell carcinoma (ESRCC) between 2010 and 2015 were abstracted from the Surveillance, Epidemiology, and End Results (SEER) database. We performed the competing risk model to select significant variables to build a competing risk nomogram, which was used to estimate 1-year, 3-year, and 5-year CSS probability. The C-index, receiver operating characteristic (ROC) curve, calibration plot, Brier score, and decision curve analysis were performed in the internal validation.

Results

A total of 564 patients with esophageal signet-ring-cell carcinoma fulfilled the eligibility criteria. The competing risk nomogram identified 4 prognostic variables, involving the gender, lung metastases, liver metastases, and receiving surgery. The C indexes of nomogram were 0.61, 0.75, and 0.70, respectively for 5-year, 3-year, and 1-year CSS prediction. The calibration plots displayed high consistency. The Brier scores and decision curve analysis respectively favored good prediction ability and clinical utility of the nomogram.

Conclusions

A competing risk nomogram for esophageal signet-ring-cell carcinoma was successfully constructed and internally validated. This model is expected to predict 1-year, 3-year, and 5-year CSS, and help oncologists and pathologists in clinical decision making and health care management for esophageal signet-ring-cell carcinoma patients.
Literature
10.
go back to reference Yoon HH, Khan M, Shi Q, Cassivi SD, Wu TT, Quevedo JF, et al. The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc. 2010;85(12):1080–9. https://doi.org/10.4065/mcp.2010.0421. Epub 2010/12/03 PubMed PMID: 21123634; PubMed Central PMCID: PMCPMC2996151.CrossRefPubMedPubMedCentral Yoon HH, Khan M, Shi Q, Cassivi SD, Wu TT, Quevedo JF, et al. The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc. 2010;85(12):1080–9. https://​doi.​org/​10.​4065/​mcp.​2010.​0421. Epub 2010/12/03 PubMed PMID: 21123634; PubMed Central PMCID: PMCPMC2996151.CrossRefPubMedPubMedCentral
18.
go back to reference Eguchi T, Bains S, Lee MC, Tan KS, Hristov B, Buitrago DH, et al. Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Patients With Stage I Non-Small-Cell Lung Cancer: A Competing Risks Analysis. J Clin Oncol. 2017;35(3):281–90. https://doi.org/10.1200/jco.2016.69.0834. Epub 2017/01/18 PubMed PMID: 28095268; PubMed Central PMCID: PMCPMC5456376.CrossRefPubMed Eguchi T, Bains S, Lee MC, Tan KS, Hristov B, Buitrago DH, et al. Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Patients With Stage I Non-Small-Cell Lung Cancer: A Competing Risks Analysis. J Clin Oncol. 2017;35(3):281–90. https://​doi.​org/​10.​1200/​jco.​2016.​69.​0834. Epub 2017/01/18 PubMed PMID: 28095268; PubMed Central PMCID: PMCPMC5456376.CrossRefPubMed
20.
go back to reference de Glas NA, Kiderlen M, Vandenbroucke JP, de Craen AJ, Portielje JE, van de Velde CJ, et al. Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients. J Natl Cancer Inst. 2016;108(5):djv366. https://doi.org/10.1093/jnci/djv366. Epub 2015/11/29 PubMed PMID: 26614095.CrossRefPubMed de Glas NA, Kiderlen M, Vandenbroucke JP, de Craen AJ, Portielje JE, van de Velde CJ, et al. Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients. J Natl Cancer Inst. 2016;108(5):djv366. https://​doi.​org/​10.​1093/​jnci/​djv366. Epub 2015/11/29 PubMed PMID: 26614095.CrossRefPubMed
22.
go back to reference Mathieu LN, Kanarek NF, Tsai HL, Rudin CM, Brock MV. Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2008). Dis Esophagus. 2014;27(8):757–63. https://doi.org/10.1111/dote.12147. Epub 2013/10/15 PubMed PMID: 24118313; PubMed Central PMCID: PMCPMC3979505.CrossRefPubMed Mathieu LN, Kanarek NF, Tsai HL, Rudin CM, Brock MV. Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2008). Dis Esophagus. 2014;27(8):757–63. https://​doi.​org/​10.​1111/​dote.​12147. Epub 2013/10/15 PubMed PMID: 24118313; PubMed Central PMCID: PMCPMC3979505.CrossRefPubMed
31.
go back to reference Du R, Ming J, Geng J, Zhu X, Zhang Y, Li S, et al. Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study. Radiat Oncol (London, England). 2022;17(1):45. https://doi.org/10.1186/s13014-022-02016-3. Epub 2022/03/05 PubMed PMID: 35241109; PubMed Central PMCID: PMCPMC8896317.CrossRef Du R, Ming J, Geng J, Zhu X, Zhang Y, Li S, et al. Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study. Radiat Oncol (London, England). 2022;17(1):45. https://​doi.​org/​10.​1186/​s13014-022-02016-3. Epub 2022/03/05 PubMed PMID: 35241109; PubMed Central PMCID: PMCPMC8896317.CrossRef
33.
34.
go back to reference Kumar NAN, Jose A, Usman N, Rajan K, Munisamy M, Shetty PS, et al. Signet ring cell cancer of stomach and gastro-esophageal junction: molecular alterations, stage-stratified treatment approaches, and future challenges. Langenbeck’s Arch Surg. 2022;407(1):87–98. https://doi.org/10.1007/s00423-021-02314-6. Epub 2021/09/11 PubMed PMID: 34505199; PubMed Central PMCID: PMCPMC8847240.CrossRef Kumar NAN, Jose A, Usman N, Rajan K, Munisamy M, Shetty PS, et al. Signet ring cell cancer of stomach and gastro-esophageal junction: molecular alterations, stage-stratified treatment approaches, and future challenges. Langenbeck’s Arch Surg. 2022;407(1):87–98. https://​doi.​org/​10.​1007/​s00423-021-02314-6. Epub 2021/09/11 PubMed PMID: 34505199; PubMed Central PMCID: PMCPMC8847240.CrossRef
Metadata
Title
Prognosis prediction in esophageal signet-ring-cell carcinoma: a competing risk analysis
Authors
Chen Chen
Zehua Wang
Yanru Qin
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02818-z

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.